ResMed Director Peter Farrell Plans Additional Insider Share Sale Under Rule 144

The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).

ResMed director Peter C. Farrell has filed a notice of proposed sale of company securities under SEC Rule 144, disclosing his intention to sell 2,000 common shares of ResMed through broker Merrill Lynch on the New York Stock Exchange. The filing shows that the shares to be sold were acquired via stock options exercised for cash in November 2024, and also details that Farrell sold a total of 4,000 ResMed shares in two prior transactions over the past three months, indicating ongoing, structured share disposals by an insider under a pre-adopted trading plan dated August 12, 2025, which may be viewed by investors as routine insider portfolio management rather than a signal of undisclosed negative information about the company.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. is a U.S.-based medical technology company focused on developing, manufacturing and distributing devices and software solutions for the treatment of sleep-disordered breathing, including sleep apnea, and other chronic respiratory conditions. The company’s products are primarily used in home care and clinical settings, with a strong presence in global markets for sleep and respiratory care, supported by cloud-connected devices and digital health platforms.

Average Trading Volume: 1,171,191

Technical Sentiment Signal: Buy

Current Market Cap: A$53.07B

For an in-depth examination of RMD stock, go to TipRanks’ Overview page.